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During the past three decades, we have witnessed remarkable advances in our understanding of the molecular
etiologies of hereditary neurodegenerative diseases, which have been accomplished by ‘positional cloning’
strategies. The discoveries of the causative genes for hereditary neurodegenerative diseases accelerated not
only the studies on the pathophysiologic mechanisms of diseases, but also the studies for the development
of disease-modifying therapies. Genome-wide association studies (GWAS) based on the ‘common disease–
common variants hypothesis’ are currently undertaken to elucidate disease-relevant alleles. Although GWAS
have successfully revealed numerous susceptibility genes for neurodegenerative diseases, odds ratios associ-
ated with risk alleles are generally low and account for only a small proportion of estimated heritability. Recent
studies have revealed that the effect sizes of the disease-relevant alleles that are identiﬁed based on compre-
hensive resequencing of large data sets of Parkinson disease are substantially larger than those identiﬁed by
GWAS. These ﬁndings strongly argue for the role of the ‘common disease–multiple rare variants hypothesis’ in
sporadic neurodegenerative diseases. Given the rapidly improving technologies of next-generation sequen-
cing next-generation sequencing (NGS), we expect that NGS will eventually enable us to identify all the variants
in an individual’s personal genome, in particular, clinically relevant alleles. Beyond this, whole genome rese-
quencing is expected to bring a paradigm shift in clinical practice, where clinical practice including diagnosis
and decision-making for appropriate therapeutic procedures is based on the ‘personal genome’. The personal
genome era is expected to be realized in the near future, and society needs to prepare for this new era.
INTRODUCTION
Neurodegenerative diseases are usually characterized by onset
in late adulthood, a slowly progressive clinical course and
neuronal loss with regional speciﬁcity in the central nervous
system. In Alzheimer disease, Parkinson disease (PD), spino-
cerebellar ataxias and amyotrophic lateral sclerosis, neurode-
generation preferentially involves the cerebral cortex,
extrapyramidal system, cerebellum and spinal cord, respect-
ively. Although the majority of neurodegenerative diseases
are sporadic, Mendelian inheritance patterns have been well
documented. Intriguingly, the clinical presentations and neuro-
pathological ﬁndings of hereditary forms of these neurodegen-
erative diseases are often indistinguishable from the sporadic
diseases, raising the possibility that common pathophysiologic
mechanisms underlie both hereditary and sporadic neurode-
generative diseases.
During the past three decades, there have been remarkable
advances in our understanding of the etiologies of hereditary
neurodegenerative diseases, which have been accomplished
by ‘positional cloning’ efforts (1–4). The identiﬁcation of
the causative genes for hereditary neurodegenerative diseases
has accelerated studies on the pathophysiologic mechanisms
of diseases and the development of disease-modifying thera-
pies based on these discoveries has now become a reality.
Molecular bases of neurodegenerative disease with
Mendelian traits
Establishment of positional cloning strategies (1–4) including
high throughput linkage analysis employing microarrays (5–6)
has further accelerated the search for the causative genes for
diseases with Mendelian traits. Furthermore, the availability
of the human genome sequence (7) has tremendously acceler-
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however, the mutations causing a substantial number of her-
editary diseases remain to be identiﬁed. In familial amyo-
trophic lateral sclerosis (FALS), in particular, its causative
genes have been identiﬁed in only 25–30% of FALS cases,
suggesting that the majority of FALS genes remain to be
identiﬁed (8–10). When the pedigree size is limited, it is dif-
ﬁcult to narrow the candidate region by linkage analysis;
hence, tremendous effort is still required to identify the causa-
tive genes based on positional cloning strategies. In diseases
such as FALS in which the clinical severity is substantial,
the number of living affected individuals is often limited.
Thus, for many disorders, we need high throughput compre-
hensive resequencing capability to identify the causative
mutations located in broad candidate regions of 10–100 Mb.
MOLECULAR BASIS OF SPORADIC
NEURODEGENERATIVE DISEASES
For sporadic neurodegenerative diseases, which comprise the
majority of the cases, we are still far from understanding
their molecular etiologies despite the clues obtained on the
basis of neuropathological ﬁndings. For example, although
we know that accumulation of senile plaques in which the b
amyloid protein is the major component underlies both spora-
dic and familial Alzheimer disease, we have little knowledge
on the molecular etiologies of sporadic Alzheimer disease.
We occasionally observe affected siblings or relatives with
neurodegenerative diseases, which raises the possibility of
involvement of genetic factors in these diseases. To identify
susceptibility genes that account for the heritability seen for
complex traits, genome-wide association studies (GWAS)
employing common single nucleotide polymorphisms (SNPs)
have been conducted. The theoretical framework for GWAS
is the ‘common disease–common variant hypothesis’, in
which common diseases are attributable in part to allelic var-
iants present in more than 1–5% of the population (11–13).
Although GWAS have successfully revealed numerous sus-
ceptibility genes for common diseases such as diabetes as well
as neurodegenerative diseases, the odds ratios associated with
these risk alleles are generally low and account for only a
small proportion of estimated heritability (14–16). It is
assumed that risk alleles with large effect size may be rare
in frequency and hard to detect by GWAS employing
common SNPs. Emerging new technologies of next-
generation sequencers will eventually enable the identiﬁcation
of all the variants including ‘rare variants’ in single subjects.
In this review, future directions for identifying disease-
relevant genetic variations on the basis of comprehensive rese-
quencing of the human genome employing the next-generation
sequencers are discussed.
ROLE OF RARE VARIANTS IN
NEURODEGENERATIVE DISEASES
The general ﬁnding that the odds ratios associated with risk
alleles identiﬁed for disease susceptibility by GWAS are low
indicates that GWAS based on the ‘common disease–
common variants hypothesis’ are not effective in identifying
genetic risks with large effect sizes. High ls, estimating recur-
rent risks for siblings of affected individuals have been
demonstrated in many diseases with complex traits, but the
genetic risk factors identiﬁed by GWAS do not account for
the high ls. Current experience with GWAS strongly suggests
that rarer variants that are hard to detect by GWAS may
account for the ‘missing’ heritability. Such rare variants may
have large effect sizes as genetic risk factors for diseases.
Thus we need a paradigm shift from the ‘common disease–
common variants hypothesis’ to a ‘common disease–multiple
rare variants hypothesis’ to identify disease-relevant alleles
with large effect sizes.
The prominent role of rare variants in neurodegenerative
disease is best highlighted by the recent discovery of the glu-
cocerebrosidase gene (GBA) as a robust genetic risk factor for
PD (17–18). PD, which is characterized by tremor, rigidity,
bradykinesia, and postural instability, is the second most
common neurodegenerative disease after Alzheimer disease,
with onset typically in late adulthood. The prevalence of PD
has been estimated to be 0.3% in the general population and
1% in people over 60 years of age. Although a-synuclein
(SNCA), leucine-rich repeat kinase 2 (LRRK2), UCHL-1,
Parkin (PARK2), PTEN-induced putative kinase 1 (PINK1)
and DJ-1 have been identiﬁed as causative genes for familial
PD, PD patients with pathogenic mutations in these genes
are rare, and most of the PD cases are sporadic, the etiologies
of which are poorly understood. A population-based study
coupled with genealogy information demonstrated that the
estimated risk ratio for PD for siblings of patients with
PD was signiﬁcantly elevated (ls ¼ 6.3), indicating that
genetic factors substantially contribute to the development of
sporadic PD (18). Recent clinical observations (19) suggested
the association of sporadic PD with heterozygous mutations
in the glucocerebrosidase gene (GBA) encoding the
enzyme that is deﬁcient in patients with Gaucher disease, an
autosomal recessive lysosomal storage disease. Furthermore
co-morbidity of PD and Gaucher disease had previously
been described (20). We conducted an extensive resequencing
analysis of GBA in PD patients and controls, and found that
GBA variants that are pathogenic for Gaucher disease confer
a robust susceptibility to sporadic PD, and, even account for
familial clustering of PD (18) (Fig. 1). The combined carrier
frequency of the ‘pathogenic variants’ was as high as 9.4%
in PD patients and signiﬁcantly more frequent than in controls
(0.37%) with a markedly high odds ratio of 28.0 (95% CI, 7.3
to 238.3) for PD patients compared with controls.
The molecular effects of the ‘pathogenic variants’ in PD
remain to be elucidated. Gain of toxic functions of the
mutant glucocerebrosidase proteins independent of enzyme
activity might be involved in the pathogenesis. Intriguingly,
however, all the variants associated with PD are ‘pathogenic
variants’ for Gaucher disease, raising the possibility that a
decreased glucocerebrosidase activity plays a role in the
pathogenesis of PD. Identiﬁcation of a splice junction
mutation, ‘IVS6+1g.a’, which is predicted to lead to a
loss of function due to a premature stop codon, in this study
may further support this notion (18).
Many GWAS have recently been conducted to identify sus-
ceptibility genes for PD. Satake et al.( 21) have recently pub-
lished the results of their GWAS on Japanese PD cases and
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LRRK2 and SNCA. As shown in the Table 1, the odds
ratios are relatively low (1.24–1.37) despite the signiﬁcant
P-values. More importantly, the GBA locus on chromosome
1 was not detected in their GWAS, presumably because rare
variants such as those in GBA are hard to detect by GWAS
using common SNPs (tag SNPs). These results provide the fol-
lowing lessons: (i) risk factors with substantially high odds
ratio are present in common diseases such as PD; (ii) rare var-
iants are present at low frequencies; (iii) multiple rare GBA
variants were detected only through comprehensive resequen-
cing of the gene; and (iv) GWAS on the same population did
not identify the locus for the susceptibility gene harboring
multiple rare variants. These data demonstrate the power of
resequencing strategies for the identiﬁcation of rare variants
in neurodegenerative disease.
As Manolio et al.( 16) recently described that GWAS have
identiﬁed hundreds of genetic variants associated with
complex human diseases and traits, and have provided
valuable insights into their genetic architecture. However,
because most variants identiﬁed to date confer relatively
small increments in risk and explain only a small proportion
of familial clustering, a remaining challenge will be to
deﬁne the genetic basis of the ‘missing’ heritability.
APPLICATION OF HIGH THROUGHPUT
RESEQUENCING FOR THE IDENTIFICATION OF
RARE GENETIC VARIANTS WITH LARGE EFFECT
SIZES
As discussed earlier, GWAS are inefﬁcient in identifying rare
variants associated with disease susceptibility and instead
whole genome resequencing will be required. For PD, clinical
observations suggested an association of PD and Gaucher
disease (19–20). Without such clinical observations,
however, comprehensive whole genome or exome resequen-
cing will be required to identify rare variants relevant to
disease. To accomplish this goal, high throughput resequen-
cing efforts employing next-generation sequencers will be
the most promising approach.
Developing next-generation sequencing technologies
The automated Sanger method is considered a ‘ﬁrst-
generation’ technology, and newer methods are referred to
as next-generation sequencing (NGS) (22). As shown in
Figure 2, the throughput of NGS is dramatically increasing.
As of 2010, the throughput is 100–200 Gb/run. Since the
cost for whole genome resequencing for a read depth sufﬁcient
to identify variants with a high accuracy is still expensive, it is
not easy to resequence the whole genome of a large number of
individuals. Thus, we need to develop strategies to efﬁciently
identify disease-relevant variants employing technologies with
high accuracy and reasonable cost.
Table 1. Comparison of allele frequencies and odds ratios of disease-relevant
variations
Variants Parkinson
disease (%)
Controls (%) Odds ratio (95%
conﬁdence interval)
GBA
a 9.4 0.4 28.0 (7.3–238.3)
SNCA (rs11931074)
b 32 42 1.50 (1.34–1.68)
LRRK2 (rs1994090)
b 11 8 1.43 (1.20–1.70)
BST1 (rs11931532)
b 45 40 1.22 (1.09–1.35)
PARK16 (rs947211)
b 43 48 1.23 (1.11–1.37)
aMitsui et al.( 18).
bSatake et al.( 21).
Figure 1. Research paradigm to identify disease-related variations based on comparison of effect sizes of variants and allele frequencies of the variants in popu-
lation. Adapted by permission from Macmillan Publishers Ltd: Nature, 461: 747–53 (2009) (16).
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ment of exons or target regions using oligonucleotide arrays or
oligonucleotide ‘bait’ in solution have been preferentially
employed. With this strategy, all exons in the genome or
selected regions implicated in disease can be efﬁciently
enriched (23–25). With this approach, more than 90% of
target regions can be enriched, and these enriched genomic
regions can be subjected to massive resequencing using
NGS. This approach is currently being intensively used for
the identiﬁcation of disease-relevant variants, cancer proﬁling
and applications to genetic diagnosis (26–34). Dihydroorotate
dehydrogenase, the causative gene for Miller syndrome, has
recently been discovered by exome resequencing employing
NGS with a mean read depth of 40× (30). Limitations of
this approach are that capture efﬁciency may not be complete
and that additional resequencing may be required to fully
cover the target regions.
Given the ever increasing throughput of NGS and the dra-
matically decreasing costs, it will soon be a realistic approach
to conduct whole genome resequencing employing NGS. To
date, whole genome sequences of at least eight individuals
have been described (35–39). These studies have shown that
there are more than 3 million SNPs in the human genome.
In one study, among the 3.3 million SNPs, 8996 known non-
synonymous SNPs and 1573 novel non-synonymous SNPs
were identiﬁed. Interestingly, 32 alleles exactly matched
mutations previously registered in the Human Gene Mutation
Database. In addition, 345 insertions/deletions were observed
to overlap the coding sequence and had the potential to alter
protein function (39). These results indicate that it will be
challenging to determine the variations that are relevant to dis-
eases among the numerous variations.
The throughput of NGS is increasing at a rapid rate and
several hundred Gb can now be generated in just one ‘run’.
The enormous amount of data will result in signiﬁcant
challenges in appropriately interpreting the data. Given the
enormous numbers of short-read sequences ( 100 bp), infor-
matics analyses including mapping to reference sequences and
identiﬁcation of variations require a huge computational
power (40–44). Furthermore, mutations can be variable includ-
ing single base substitutions, insertions/deletions and structural
variations. It is difﬁcult to efﬁciently identify all the variations
usingcurrentlyavailablesoftware.Functionalannotationofvar-
iants identiﬁed in NGS will be important, and availability of
databases containing variations and the functional annotation
will be needed.
With current NGS, it is important to realize that there are
error reads inherently associated with these technologies.
Although the average rates of error are less than 0.1–0.2%,
it is essential to minimize errors before attempting to identify
disease-relevant variations. With increasing sequencing depth,
error rate substantially decreases, but some errors remain and
the error rates may depend on sequencing cycles, sequence
context and other factors (45,46).
Application of NGS for diseases with Mendelian traits
Lupski et al.( 47) has recently applied whole genome rese-
quencing to identify the causative mutation for a family with
a recessive form of Charcot–Marie–Tooth disease. They
sequenced the whole genome of the proband, identiﬁed all
potential functional variants in genes likely to be related to
the disease, and identiﬁed and validated compound, heterozy-
gous, causative alleles in SH3TC2 (the SH3 domain and tetra-
tricopeptide repeats 2 gene), involving two mutations, in the
proband and the other affected family members. This study
strongly encourages future applications of NGS to identify
causative genes for Mendelian diseases (Fig. 3).
Application of NGS to sporadic diseases
To identify disease-relevant variants in sporadic diseases, it is
essential to analyze larger sample sizes of cases and controls
than those needed to identify causative genes for diseases
with Mendelian traits. The number of individuals needed to
identify disease-relevant variants will depend on the odds
ratio of the disease-related alleles and the allele frequencies
in the population. In the case of GBA as the risk factor for
PD (described above), initial screening of 100 PD patients
and 100 controls was sufﬁcient to identify this gene as a
risk factor for PD (18). In addition, we occasionally observe
patients with familial aggregation (48,49). Because disease-
relevant alleles with large effect sizes seem to underlie
familial clustering, such cases should be good candidates to
apply comprehensive resequencing with NGS.
As shown in the road map in Figure 3, we may need to wait
until the cost for resequencing goes down substantially to
apply whole genome resequencing to identify disease-relevant
variants for sporadic diseases. To lessen the cost burden,
whole exome analysis of a large number of samples is an
alternative approach. Analysis of pooled DNAs may also be
an alternate approach (45).
CONCLUSION
As discussed earlier, whole genome resequencing is a promis-
ing strategy for identifying causative genes and clinically rel-
evant variations. Beyond this, whole genome resequencing is
expected to bring a paradigm shift in clinical practice, where
the diagnosis and decision-making for appropriate therapeutic
procedures is based on the ‘personal genome’. The realization
of ‘personal genome’ era is expected to come soon, and the
Figure 2. Increased throughput of next-generation sequencers.
R68 Human Molecular Genetics, 2010, Vol. 19, Review Issue 1genetics community needs to prepare for this exciting new era
in genetics research.
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